Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Defence Therapeutics ( (TSE:DTC) ) is now available.
Defence Therapeutics has launched a private placement of up to 20,000,000 units at $0.55 each, for gross proceeds of up to $11 million, with each unit comprising one common share and one warrant exercisable at $0.65 for 24 months. The company has secured a binding term sheet with two institutional investors for $6 million, which will be placed in escrow and released to Defence in 18 monthly tranches, with the ultimate proceeds varying based on the company’s share price relative to a benchmark.
Under the sharing agreement, approximately 606,060 shares will be released monthly over the 18‑month term, and Defence may receive more or significantly less than the initial $6 million depending on future market performance, though no additional shares will be issued if the price falls. The financing structure includes warrant exercise caps to limit any investor’s stake below 9.99% and fees payable in cash or units, and the company plans to deploy the funds to advance its ADC and radiopharmaceutical pipelines, pursue partnerships, and support working capital, subject to CSE approval and resale restrictions on the securities issued.
The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.
Spark’s Take on TSE:DTC Stock
According to Spark, TipRanks’ AI Analyst, TSE:DTC is a Neutral.
The score is primarily constrained by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals are mixed with short-term stabilization but longer-term weakness, and valuation provides limited support due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:DTC stock, click here.
More about Defence Therapeutics
Defence Therapeutics Inc. is a publicly traded biotechnology company specializing in precision intracellular drug delivery technologies. The company focuses on developing Antibody-Drug Conjugate and radiopharmaceutical programs, positioning itself within the oncology and advanced therapeutics market, and aims to expand through partnerships and continued R&D investment.
Average Trading Volume: 50,970
Technical Sentiment Signal: Sell
Current Market Cap: C$36.14M
Find detailed analytics on DTC stock on TipRanks’ Stock Analysis page.